Home/Investors/Hillhouse Capital

Hillhouse Capital

Biotech Investor · 55 portfolio companies

Portfolio
55
Combined Value
$142.2B
Focus Areas
31
Top Stage
phase-2

Portfolio Companies

CompanyValuation
Innovent Biologics$142.2B
Genocury Biotech
VivaVision Biotech
Tenacia Biotechnology
Ocumension Therapeutics
Nuance Pharma
Lyvgen Pharma
Lepu Biopharma
InventisBio
Immorna Biotherapeutics
Laekna Therapeutics
Dizal Pharma
GenFleet Therapeutics
Full-Life Technologies
EpimAb Biotherapeutics
Duality Biologics
Drug Farm
CStone Pharmaceuticals
Convalife Pharmaceuticals
Abbisko Therapeutics
Broncus Medical
Biocytogen
Thousand Oaks Biopharmaceuticals
Vazyme
Vazyme
TransThera Sciences
Eaglenos Sciences
Biosion
HighTide Therapeutics
Viva Biotech
Quaero Life Science
AccuPulse
Innorna
APRINOIA Therapeutics
Yirui Pharma
Sciwind Biosciences
Lynk Pharmaceuticals
HighField Biopharmaceuticals
Xiangxue Life Sciences
MingMed Biotechnology
Excelmab
Fapon Biotech
Sintaho Pharmaceutical
Keymed Biosciences
TransGen Biotech
Surgerii Robotics
MegaRobo
InnoCare
Genetron Health
Coyote Bioscience
BroadenBio
AffaMed Therapeutics
Avistone
Tianhu Technology
CSR Biotech